This trial is testing a new drug for Crohn's disease in both people who have never taken a biologic drug and people who have. The goal is to see if it is safe and effective. People who finish the study or don't respond well can enter a long-term extension study.
4 Primary · 10 Secondary · Reporting Duration: Week 26 (predose or postdose) and Week 58 predose
1374 Total Participants · 4 Treatment Groups
Primary Treatment: Filgotinib · Has Placebo Group · Phase 3
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: